Jianmeng Wang Xiujuan Wu Hui Deng Ye Liu Hongping Liu Xueli Fan Kangding Liu Jiang Wu Hong-Liang Zhang
10.17712/nsj.2016.1.20150483
Neurosciences (Riyadh)
2016 Jan;21(1):77-8.
CC BY-NC-SA
https://pubmed.ncbi.nlm.nih.gov/26818174/
Dendritic Cell Sarcoma, Follicular / pathology Immunologic Factors / therapeutic use Lymph Nodes / pathology Myasthenia Gravis / drug therapy Rituximab / therapeutic use
Dendritic Cell Sarcoma, Follicular / pathology Immunologic Factors / therapeutic use Lymph Nodes / pathology Myasthenia Gravis / drug therapy Rituximab / therapeutic use Case Reports Autoantibodies / immunology Axilla Dendritic Cell Sarcoma, Follicular / complications Female Humans Middle Aged Myasthenia Gravis / etiology Myasthenia Gravis / immunology Neck Receptor Protein-Tyrosine Kinases / immunology Receptors, Cholinergic / immunology Treatment Outcome Autoantibodies Immunologic Factors Receptors, Cholinergic Rituximab MUSK protein, human Receptor Protein-Tyrosine Kinases
PMC5224420
26818174
Response to rituximab in an anti-muscle-specific receptor tyrosine kinase- and anti-acetylcholine recepto-double-positive myasthenia gravis patient concomitant with follicular dendritic cell sarcoma
2016